Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother?s vaccination in pregnancy in infants aged 2-11 months
Por:
Merdrignac L, Acosta L, Habington A, Garcìa Cenoz M, Pandolfi E, Fabiánová K, Jordán-García I, O'Sullivan N, Navasués A, Tozzi AE, Zavadilová J, Jané M, Cotter S, Pitillas NI, Rizzo C, Krížová P, Hanslik T, Munoz-Almagro C, Pastore L, Bacci S, Moren A and Valenciano M
Publicada:
19 oct 2022
Ahead of Print:
1 oct 2022
Resumen:
Background: PERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended pertussis vaccination in pregnancy. Among infants aged <2 months, we measured the vaccine effectiveness (VE) in pregnancy; among infants aged 2-11 months, VE of vaccination in pregnancy and of primary vaccination (PV).Methods: From December 2015 to 2019, we included all infants aged <1 year presenting with pertussis-like symptoms. Using a test-negative-design, cases were infants testing positive for Bordetella pertussis by PCR or culture. Controls were those testing negative for all Bordetella species. Vaccinated mothers were those who received vaccine in pregnancy. Vaccinated infants were those who received >= 1 dose of PV > 14 days before symptom onset. We excluded infants with unknown maternal or PV status or with mothers vaccinated <= 14 days before delivery. We calculated pooled VE as 100 * (1-odds ratio of vaccina-tion) adjusted for study site, onset date in quarters and infants' age group.Results: Of 829 infants presenting with pertussis-like symptoms, 336 (41%) were too young for PV. For the VE in pregnancy analysis, we included 75 cases and 201 controls. Vaccination in pregnancy was recorded for 9 cases (12%) and 92 controls (46%), adjusted VE was between 75% [95%CI: 35-91%] and 88% [95%CI: 57-96%]. Of 493 infants eligible for PV, we included 123 cases and 253 controls. Thirty-one cases and 98 controls recorded both PV with >= 1 dose and vaccination in pregnancy, adjusted VE was between 74% [95%CI: 33-90] and 95% [95%CI: 69-99]; 27 cases and 53 controls recorded PV only, adjusted VE was between 68% [95%CI: 27-86] and 94% [95%CI: 59-99]. Conclusion: Our findings suggest that vaccination in pregnancy reduces pertussis incidence in infants too young for PV. In infants aged 2-11 months, PV only and both PV and vaccination in pregnancy provide significant protection against severe pertussis.(c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Filiaciones:
Merdrignac L:
Epidemiology Department, Epiconcept, Paris, France
Acosta L:
Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain
Universitat Politècnica de Catalunya- BarcelonaTech (UPC), Barcelona, Spain
Habington A:
Children's Health Ireland, Crumlin, Dublin, Ireland
Garcìa Cenoz M:
Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
Pandolfi E:
Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children Hospital, Rome, Italy
Fabiánová K:
National Institute of Public Health, Prague, Czech Republic
Jordán-García I:
Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
University of Barcelona, Barcelona, Spain
O'Sullivan N:
Children's Health Ireland, Crumlin, Dublin, Ireland
Navasués A:
Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
Tozzi AE:
Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children Hospital, Rome, Italy
Zavadilová J:
National Institute of Public Health, Prague, Czech Republic
Jané M:
Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain
CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
University of Barcelona, Barcelona, Spain
Cotter S:
Health Protection Surveillance Centre, Dublin, Ireland
Pitillas NI:
Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
Rizzo C:
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
Krížová P:
National Institute of Public Health, Prague, Czech Republic
Hanslik T:
Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
Munoz-Almagro C:
Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain
Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain
Pastore L:
European Centre for Diseases Control and Prevention, Stockholm, Sweden
Bacci S:
European Centre for Diseases Control and Prevention, Stockholm, Sweden
Moren A:
Epidemiology Department, Epiconcept, Paris, France
Valenciano M:
Epidemiology Department, Epiconcept, Paris, France
Epidemiology Department, Epiconcept, Paris, France.
Green Submitted, hybrid
|